North America Anticoagulant Reversal Drug Market Dynamics and Trends by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

North America Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)

  • Report Date : May 2021
  • Report Code : TIPRE00022198
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 131
Page Updated: May 2021

The anticoagulant reversal drug market in North America is expected to grow from US$ 414.7 million in 2019 to US$ 1,037.9 million by 2027; it is estimated to grow at a CAGR of 12.8% from 2019 to 2027.



The US, Canada, and Mexico are major economies in North America. Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding. As per the Centers for Disease Control and Prevention (CDC), in 2018, in the US, AFib was mentioned on around 175,326 death certificates and was the primary cause of death in about 25,845 of those deaths. Additionally, it has also anticipated that 12.1 million people in the US will have AFib by 2030.

According to the report "Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific," from Biosense Webster (part of Johnson & Johnson Medical Devices Companies), atrial fibrillation is projected to affect around 72 million people by 2050. Thus, such high prevalence of atrial fibrillation is likely to favor the growth of the market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The North America anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.


21848-img1

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

North America Anticoagulant Reversal Drug Market Segmentation     

By Product

  • Prothrombin Complex Concentrates
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Country

  • North America

    • US
    • Canada
    • Mexico

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Octapharma AG
  • AMAG PHARMACEUTICALS, INC.
  • Fresenius Kabi AG
  • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  • CSL Limited
  • Grifols, S.A.

North America Anticoagulant Reversal Drug Report Scope

Report Attribute Details
Market size in 2019 US$ 414.7 Million
Market Size by 2027 US$ 1,037.9 Million
Global CAGR (2019 - 2027) 12.8%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Product
  • Prothrombin Complex Concentrates
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
By End User
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Octapharma AG
  • AMAG PHARMACEUTICALS, INC.
  • Fresenius Kabi AG
  • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  • CSL Limited
  • Grifols, S.A.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
ISO Certified Logo